Video

Dr. Bendell on c-MET Inhibition in Hepatocellular Carcinoma

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses c-MET inhibition in hepatocellular carcinoma.

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses c-MET inhibition in hepatocellular carcinoma (HCC).

A randomized phase II study compared tivantinib, a c-MET tyrosine kinase inhibitor (TKI), to best supportive care in the second-line setting for patients with advanced HCC. Patients with MET-high HCC saw improvement in progression-free survival and overall survival. There is a need for further exploration of anti-c-MET drugs for this patient population, Bendell says.

A phase I/II study from the 2013 Gastrointestinal Cancers Symposium combined E7050 (golvantinib), a c-MET and VEGFR TKI, with sorafenib, the standard of care for patients with advanced HCC. The phase I portion of the trial has been completed and is now moving on to phase II.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center